← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,677	+31	+0.9%	$321B
2	2 Pfizer PFE $168B	3,195	-68	-2%	$197B
3	3 AbbVie ABBV $501B	3,051	+69	+2%	$195B
4	4 Merck MRK $358B	2,952	+49	+2%	$152B
5	5 Bristol-Myers Squibb BMY $124B	2,515	+70	+3%	$119B
6	6 Amgen AMGN $235B	2,336	+43	+2%	$102B
7	7 Gilead Sciences GILD $195B	1,599	-82	-5%	$59.2B
8	8 Novartis NVS $286B	1,137	-9	-0.8%	$18.3B
9	9 Regeneron Pharmaceuticals REGN $82B	1,095	+17	+2%	$64.5B
10	10 AstraZeneca AZN $259B	983	+33	+3%	$34.3B
11	11 GSK GSK $98.2B	930	+11	+1%	$14.4B
12	12 DELISTED Exact Sciences EXAS	559	-37	-6%	$11.7B
13	13 Incyte INCY $23B	533	+7	+1%	$16.4B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	505	-20	-4%	$24B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	462	+8	+2%	$8.87B
16	16 Exelixis EXEL $15.6B	363	+34	+10%	$6.11B
17	17 Guardant Health GH $22.3B	356	-40	-10%	$6.12B
18	18 Halozyme HALO $13.8B	318	-7	-2%	$5.12B
19	19 Qiagen QGEN $9.53B	293	-8	-3%	$6.39B
20	20 Takeda Pharmaceutical TAK $62.1B	288	-11	-4%	$807M
21	21 BioNTech BNTX $22.7B	287	-67	-19%	$5.9B
22	22 Natera NTRA $58.3B	286	-45	-14%	$3.76B
23	23 NeoGenomics NEO $2.22B	279	-28	-9%	$1.36B
24	24 Lantheus LNTH $6.53B	276	+79	+40%	$3.67B
25	MRTX 25 DELISTED Mirati Therapeutics, Inc. Common Stock MRTX	253	-7	-3%	$4.71B